22.01.2010 • News • Intercell • GlaxoSmithKline (GSK) • GSK

Intercell, GSK team up for Patch Vaccines

Britain's Glaxosmithkline said it was teaming up with Austrian vaccine maker Intercell to develop patch vaccines that can be delivered without needles. GSK will make an up-front cash contribution of €33.6 million and an equity investment of up to €84 million via staggered share purchases of up to 5% of the company. The deal will include Intercell's candidate vaccine for travellers' diarrhea, which is currently in final stage clinical trials, and a potential single application pandemic flu vaccine which is in Phase II trials. The firms said they would also be exploring the use of the patch technology for other vaccines in GSK's portfolio.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Top-Feature

most read